Pembrolizumab shows efficacy in advanced triple-negative breast cancer patients

SAN ANTONIO – Roughly one in five women with heavily pretreated, advanced triple-negative breast cancer experienced a durable response to monotherapy using the novel immune checkpoint inhibitor...